

Invitation to Vitrolife Group's presentation of the Q3 2026 interim report

Vitrolife AB (publ) will publish its Q3 2026 interim report on Thursday, 22 October 2026 at 08:00 am CET. A conference call for investors, analysts and financial media will be held at 10:00 am CET the same day.

The presentation will be held in English by Bronwyn Brophy O'Connor, CEO, and Pär Ihrskog, CFO. The conference call will begin with a presentation of the report followed by a question-and-answer session. The presentation material will be available prior to the start of the conference call on the Vitrolife Group website www.vitrolifegroup.com.

To follow the webcast, please use this [link](#).

To participate in the conference call please register via this [link](#). After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.

After the event, the presentation material and a recording of the webcast will be available at www.vitrolifegroup.com.

Gothenburg, 7 October 2026
VITROLIFE AB (publ)

Contact:

Cecilia Möllerstrandh

Investor Relations

investors@vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

About Us

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,150 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden.
Corporate identity number 556354-3452. Tel: +46 31 721 80 00.
E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.

Attachments

Invitation to Vitrolife Group's presentation of the Q3 2026 interim report